🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against superbug strains of the pathogen, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are increasing globally, with data suggesting in excess of 82 million infections per year. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the face of increasing worldwide cases, escalating drug resistance and the very limited treatment choices at this time.”

Health officials are deeply concerned about the rise in drug-resistant strains. The World Health Organization has designated it as a "high-priority threat". Recent surveillance showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, was also approved in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a unique collaborative effort for drug creation. The non-profit organisation GARDP worked alongside the drug firm its industry partner to see it through.

“This authorization marks a huge turning point in the therapy of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Results and Global Access

As per findings detailed in a prominent scientific publication, the new drug successfully treated more than 90% of cases of the STI. This puts it on an equal footing with the typical regimen, which combines an injection and a pill. The trial included nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have expressed positive views. Access to a one-pill regimen such as this is hailed as a "revolutionary step" for gonorrhoea control. This is deemed essential to lessen the impact of the disease for individuals and to stop the proliferation of untreatable gonorrhoea globally.